FLCN and Birt-Hogg-Dube syndrome: In order to provide the foundation for the development of a therapeutic approach for treatment of BHD patients, his group has studied the FLCN gene pathway and identified FLCN-interacting binding partners, co-chaperones FNIP1 and FNIP2, and shown that FLCN regulates activation and nuclear translocation of TFE3 [9–19].